Related Experiment Videos
Alzheimer's disease: the pharmacological pathway
Hervé Allain1, Danièle Bentué-Ferrer, Olivier Tribut
1Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Université de Rennes I, CS 34317, 35043 Rennes cedex, France. herve.allain@univ-rennes1.fr
Fundamental & Clinical Pharmacology
|August 14, 2003
Summary
Current Alzheimer's disease (AD) treatments target the cholinergic system. Future therapies focus on AD's pathophysiology, including beta-amyloid and tau tangles, for early intervention.
Area of Science:
- Neuroscience
- Pharmacology
- Drug Discovery
Background:
- Current Alzheimer's disease (AD) pharmacological treatments are limited to cholinesterase inhibitors, based on the cholinergic hypothesis.
- AD pathophysiology involves neuronal degeneration, beta-amyloid plaques, and tau-rich neurofibrillary tangles.
Purpose of the Study:
- To review emerging drug discovery pathways for Alzheimer's disease.
- To explore novel therapeutic targets beyond the cholinergic system.
Main Methods:
- Literature review of current and future Alzheimer's disease drug discovery strategies.
- Analysis of six key entry pathways for novel therapeutic compounds.
Main Results:
- Identified six main pathways for AD drug discovery: supplementation therapy, anti-apoptotic compounds, mitochondrial-acting substances, anti-amyloid agents, anti-protein aggregation compounds, and lipid-lowering drugs.
- Emphasized the need for early intervention with new curative drugs.
Conclusions:
- Future Alzheimer's disease treatments will target core pathological mechanisms.
- The development and availability of novel AD therapeutics depend on pharmaceutical industry policies.